Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis

Neoplasia

Volumn 3, Issue 6, 2001, Pages 459-468

  Fingleton, Barbara ^a   Vargo Gogola, Tracy ^a   Crawford, Howard C ^a   Matrisian, Lynn M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug resistance; Fas ligand; Immune surveillance; Matrix metalloproteinase; Tumor progression

Indexed keywords

FAS ANTIBODY; FAS ANTIGEN; MATRILYSIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CELL DEATH; CELL LINE; CELL PROLIFERATION; DNA MODIFICATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPLEEN CELL; TUMOR GROWTH;

EID: 0035216956     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900190     Document Type: Article

References (60)

1. The hallmarks of cancer
2. Apoptosis in cancer
3. Matrix metalloproteinases
4. Matrix metalloproteinases: Biologic activity and clinical implications
5. Matrix metalloproteinases as emerging targets in anticancer therapy: Status and prospects
6. Changing views of the role of matrix metalloproteinases in metastasis
7. Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention
8. Matrilysin: An epithelial matrix metalloproteinase with potentially novel functions
9. Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis
10. Matrilysin gene expression in sporadic and familial colorectal adenomas
11. Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas
12. Matrilysin expression in human prostate carcinoma
13. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response
14. Induction of matrix metalloprotease-7 is common in mucinous ovarian tumors including early stage disease
15. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin
16. The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis
17. Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption
18. The metalloproteinase matrilysin (MMP-7) proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis
19. Apoptosis signaling by death receptors
20. Tumor expression of Fas ligand (CD95L) and the consequences
21. The collagenase gene family in humans consists of at least four members
22. Construction and use of a safe and efficient amphotropic packaging cell line
23. Matrilysin and cyclooxygenase-2 are differentially expressed in intestinal and colorectal neoplasms
24. Epithelial cell cultures from normal glandular tissue of mice
25. Morphotypic plasticity in vitro and in nude mice of epithlial mouse mammary cells (NMuMG) displaying an epithelioid (e) or a fibroblastic (f) morphology in culture
26. Isolation and characterization of a spontaneously transformed malignant mouse mammary epithelial cell line in culture
27. A cell line (HBL 100) established from human breast milk
28. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells
29. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium
30. Over-expression of Fas ligand (FasL) during malignant transformation in the large bowel and in Barrett's metaplasia of the esophagus
31. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity
32. Cleavage of beta 4 integrin by matrilysin
33. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1
34. Expression of Fas (CD95/APO-1) ligand by human breast cancers: Significance for tumor immune privilege
35. Downregulation of Fas ligand by shedding
36. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity
37. Differential activity of soluble versus cellular Fas ligand: Regulation by an accessory molecule
38. Ionizing radiation and chemotherapeutic drugs induce apoptosis in lymphocytes in the absence of Fas or FADD/MORT1 signaling. Implications for cancer therapy
39. Myeloma cells selected for resistance to CD95mediated apoptosis are not cross-resistant to cytotoxic drugs: Evidence for independent mechanisms of caspase activation
40. Induction of apoptosis by cancer chemotherapy
41. Regulation of FasL by NF-kappaB and AP-1 in Fas-dependent thymineless death of human colon carcinoma cells
42. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity
43. The immune system as antitumor sentinel: Molecular requirements for an anti-tumor immune response
44. The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors - Lessons from normal and immunodeficient mice
45. Proapoptotic functions of cytotoxic lymphocyte granule constituents in vitro and in vivo
46. Fas ligand-mediated killing by intestinal intraepithelial lymphocytes
47. Fas and Fas ligand interactions suppress melanoma lung metastasis
48. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein
49. Promoter region methylation does not account for the frequent loss of expression of the Fas gene in colorectal carcinoma
50. Decreased Fas antigen receptor expression in testicular tumor cell lines derived from polyomavirus large T-antigen transgenic mice
51. Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells
52. Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma
53. Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes
54. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival
55. Role of Fas ligand (CD95L) in immune escape: The tumor cell strikes back
56. Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape
57. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape
58. Fas ligand expression in primary colon adenocarcinomas: Evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer
59. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion?
60. The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma